Page 49 - Programme book for The International Liver Congress 2015, EASL ILC 2015

Joint Workshop: EASL-International PSC study group Schubert 3

Chairs:
Tom Karlsen, Norway
Cyriel Ponsioen, The Netherlands

8:00 - 8:30 A brief history of prognostic models and clinical trial end- SCIENTIFIC PROGRAMME
points in PSC
8:30 - 9:00 Olivier Chazouillères, France
9:00 - 9:30
9:30 – 10:00 Regulatory aspects of clinical trial end-point considerations
10:00 - 10:30 Elmer Schabel, Germany
10:30 - 11:00
Does a PSC specific fibrosis biomarker profile exist?
Morten Karsdal, Denmark

Coffee Break

End-point strategies for anti-fibrotics in NASH - lessons for PSC
Massimo Pinzani, The United Kingdom

Discussion

Joint Workshop: EASL-INHSU Schubert 4

Chairs:
Olav Dalgard, Norway
Cihan Yurdaydin, Turkey

8:00 - 8:30 Somatic illness in PWID -the impact of liver disease
8:30 - 9:00 Kunt Boe Kielland, Norway
9:00 - 9:30
9:30 – 10:00 Screening for fibrosis among PWID
10:00 - 10:30 Peer Brehm Christensen, Denmark
10:30 - 11:00
HCV treatment to PWID-results from the ACTIVATE trial
Gregory Dore, Australia

Coffee Break

Reinfection following SVR
Xiomara Thomas, The Netherlands

Interventions to prevent HCV transmission
Sharon Hutchinson, The United Kingdom

Vienna, Austria • April 22–26, 2015 49